What Is Prolia? Uses, Dosage, and What You Need to Know in 2026

Prolia is a prescription medication used to treat osteoporosis and prevent fractures in patients at high risk. It belongs to a category of medications called RANKL inhibitors — a type of monoclonal antibody that targets specific proteins in the bone remodeling process. Here's a complete patient-friendly guide to what Prolia is, what it does, and how it's used.

What Is Prolia (Denosumab)?

Prolia is the brand name for denosumab, a human monoclonal antibody manufactured by Amgen Inc. It was FDA-approved on June 1, 2010, making it one of the first biologic treatments specifically approved for osteoporosis. Unlike bisphosphonate pills, Prolia is injected under the skin once every 6 months at a doctor's office or clinic.

Prolia works by blocking RANKL, a protein that promotes the formation and activity of osteoclasts — the cells responsible for breaking down bone. By inhibiting RANKL, Prolia slows bone breakdown, increases bone density, and reduces fracture risk.

What Is Prolia Approved to Treat?

Prolia is FDA-approved for five indications:

1. Postmenopausal women with osteoporosis at high risk for fracture — reduces vertebral, non-vertebral, and hip fractures.
2. Men with osteoporosis at high risk for fracture.
3. Glucocorticoid-induced osteoporosis in men and women who are starting or continuing corticosteroids at 7.5 mg/day prednisone equivalent or more.
4. Men with prostate cancer on androgen deprivation therapy (ADT) at high risk for fracture.
5. Women with breast cancer on adjuvant aromatase inhibitor therapy at high risk for fracture.

Prolia Dosage and How It's Given

Prolia comes as a 60 mg/mL solution in a single-dose prefilled syringe. It is injected subcutaneously (under the skin) in the upper arm, upper thigh, or abdomen, once every 6 months. The injection must be given by a trained healthcare provider — patients do not self-administer Prolia at home.

If a dose is missed, the injection should be given as soon as possible. Subsequent doses should then be scheduled 6 months from the date of the late injection — not from the originally planned date.

Prolia vs. Xgeva: Are They the Same?

Both Prolia and Xgeva contain denosumab, but they are NOT interchangeable. Xgeva is used for different conditions — it prevents skeletal-related events in cancer patients with bone metastases and treats giant cell tumors of bone. Xgeva is dosed at 120 mg monthly, while Prolia is dosed at 60 mg every 6 months. Patients receiving Prolia should never receive Xgeva at the same time.

Prolia Biosimilars: What's Now Available

As of 2026, nine FDA-approved biosimilar versions of Prolia are on the market. Biosimilars contain the same active ingredient (denosumab), work the same way, and are approved based on evidence of comparable safety and efficacy. Several — including Jubbonti (denosumab-bbdz) — have been designated as interchangeable biosimilars, meaning pharmacists can substitute them without a new prescription in states that permit this.

Important Safety Information

Before starting Prolia, discuss with your doctor:

• Whether you have low blood calcium (hypocalcemia) — Prolia is contraindicated if untreated
• Any kidney problems (especially advanced CKD or dialysis)
• Pregnancy or plans to become pregnant — Prolia is contraindicated in pregnancy
• Dental health — see a dentist before starting treatment
• All medications you take — Prolia interacts with immunosuppressants and other calcium-lowering drugs

Want to understand the science? See: How Does Prolia Work? Mechanism of Action Explained.

If you're having trouble finding a provider to administer Prolia, medfinder can help you locate one near you quickly.